<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090465</url>
  </required_header>
  <id_info>
    <org_study_id>DE-Picato NIS-2013</org_study_id>
    <nct_id>NCT02090465</nct_id>
  </id_info>
  <brief_title>Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks</brief_title>
  <official_title>Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of treatment success and quality of life in patients with actinic keratoses under
      therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional (observational) study (NIS), non-controlled, prospective cohort study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Actinic keratosis</measure>
    <time_frame>8 weeks</time_frame>
    <description>Documentation of the course of actinic keratoses and skin findings during ambulant routine use of Picato®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patient' s quality of life during ambulant routine use of Picato®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosage of Picato®</measure>
    <time_frame>8 weeks</time_frame>
    <description>Prescribed and applied dosages and adherence during ambulant routine use of Picato®</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>all eligible patients</arm_group_label>
    <description>Treatment with Picato according to Summary of Product Characteristics (SmPC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol Mebutate</intervention_name>
    <description>No intervention: observation of routine use of Picato®</description>
    <arm_group_label>all eligible patients</arm_group_label>
    <other_name>Picato®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with actinic keratosis contacting their dermatologist
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Non-hyperkeratotic, non-hypertrophic actinic keratoses where treatment with Picato® is
        indicated and the treatment is intended by physicians.

        Exclusion Criteria:

          -  Preceding use of Picato® on the area planned for treatment

          -  Any other specific local treatment of actinic keratoses on the area planned for
             treatment during the last 8 weeks

          -  Melanoma, squamous cell carcinoma or spinalioma on the area planned for treatment

          -  Open wounds on the area planned for treatment

          -  Contraindications according to prescribing information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Diepgen, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Gilzinger</last_name>
    <phone>0049 6102 201-0</phone>
    <phone_ext>117</phone_ext>
    <email>andreas.gilzinger@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg/Klinische Sozialmedizin</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas L. Diepgen, Prof.Dr.med.</last_name>
      <phone>+49 6221568751</phone>
      <email>thomas.diepgen@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Thomas L Diepgen, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

